{"gene":"COG2","run_date":"2026-04-28T17:28:53","timeline":{"discoveries":[{"year":1994,"finding":"The LDLC protein (now known as COG2/ldlCp) is a peripheral Golgi protein (~83 kDa) whose association with the Golgi is brefeldin A-sensitive. In ldlB cells, ldlCp is expressed at normal levels but is not associated with the Golgi, indicating that its Golgi localization is LDLB (COG1)-dependent. Loss of ldlCp causes pleiotropic defects in multiple medial and trans Golgi-associated processes, including abnormal N- and O-linked glycoprotein synthesis.","method":"cDNA cloning, immunofluorescence with anti-ldlCp antibodies, brefeldin A treatment, somatic cell genetics with ldlB/ldlC CHO mutants","journal":"The Journal of cell biology","confidence":"High","confidence_rationale":"Tier 1-2 — original cloning and localization study with multiple orthogonal methods (cDNA complementation, immunofluorescence, BFA treatment, cross-cell-line analysis)","pmids":["7962052"],"is_preprint":false},{"year":2002,"finding":"COG2 (ldlCp) is a core subunit of the conserved oligomeric Golgi (COG) complex, which also contains COG1/ldlBp, COG3/Sec34, COG4, COG5/GTC-90, COG6, COG7, and COG8. The COG complex is required for normal Golgi morphology; EM of ldlB and ldlC mutants showed Golgi structural defects. Purified COG complex revealed an ~37-nm structure with two globular domains connected by smaller extensions.","method":"Biochemical co-purification, EM (conventional and deep-etch), genetic complementation of ldlB/ldlC CHO mutants, homology analysis","journal":"The Journal of cell biology","confidence":"High","confidence_rationale":"Tier 1-2 — complex reconstitution/purification, structural EM, and genetic validation across multiple subunits in the same study","pmids":["11980916"],"is_preprint":false},{"year":2004,"finding":"Within the COG complex, COG2 directly interacts with COG1, COG3, and COG4 as determined by in vitro translation and co-immunoprecipitation. COG4 serves as a core component interacting with COG1, COG2, COG5, and COG7; COG3 is incorporated via direct interaction with COG1 and COG2.","method":"In vitro translation, co-immunoprecipitation of individual COG subunit pairs","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 2 — systematic binary interaction mapping by reciprocal co-IP covering all eight subunits","pmids":["15047703"],"is_preprint":false},{"year":2006,"finding":"COG complex (including COG2) functions in retrograde vesicular trafficking within the Golgi apparatus. COG mutations impair the retrograde flow of resident Golgi proteins needed to maintain normal Golgi structure and function, explaining defects in glycoprotein modification.","method":"Review/synthesis integrating yeast, worm, fly, and mammalian genetic and cell biological data; pathway epistasis","journal":"Trends in cell biology","confidence":"Medium","confidence_rationale":"Tier 2-3 — model based on synthesis of genetic and trafficking data across organisms; no single direct experiment in this review paper but reflects consensus from multiple labs","pmids":["16406524"],"is_preprint":false},{"year":2007,"finding":"COG2 interacts directly with the vesicle-tethering protein p115 (via the HR2 domain of p115). This p115–COG2 interaction is required for Golgi ribbon reformation after disruption by p115 knockdown or brefeldin A treatment; the interaction occurs only in interphase cells and not in mitotic cells.","method":"Co-immunoprecipitation, p115 deletion mutant expression in p115-knockdown cells, Golgi morphology rescue assays, cell-cycle analysis","journal":"Traffic (Copenhagen, Denmark)","confidence":"High","confidence_rationale":"Tier 2 — reciprocal co-IP with deletion mapping, functional rescue of Golgi morphology, and cell-cycle specificity demonstrated in same study","pmids":["17274799"],"is_preprint":false},{"year":2010,"finding":"In Cog2-null (ldlC) CHO cells, sphingomyelin (SM) content is reduced to ~25% of wild-type. Sphingomyelin synthase (SMS1) is mislocalized from the Golgi to vesicular cytoplasmic structures in ldlC cells, and ceramide levels are 3-fold elevated, indicating that COG2 is required for proper delivery of ceramide to SMS1 at the Golgi for SM synthesis. Transfection of COG2 rescues SM levels and SMS1 Golgi localization.","method":"SM content measurement, SMS activity assays, fluorescence microscopy of transfected SMS1 and CERT, exogenous C6-NBD-ceramide assay, COG2 rescue transfection in ldlC cells","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1-2 — multiple orthogonal biochemical and cell biological assays including genetic rescue in Cog2-null cells","pmids":["21047787"],"is_preprint":false},{"year":2010,"finding":"In Cog2-null (ldlC) CHO cells, GM3 synthesis is specifically blocked due to mislocalization of the lactosylceramide sialyltransferase SialT1 from the Golgi. Co-immunoprecipitation revealed a COG2-mediated interaction between SialT1 and the COG complex subunit COG1, indicating COG2 is required for proper Golgi cycling of glycolipid glycosyltransferases.","method":"Biochemical GM3 quantification, SialT1 enzyme activity assays, immunocytochemistry of SialT1 localization, co-immunoprecipitation of SialT1 with COG1","journal":"Neurochemical research","confidence":"High","confidence_rationale":"Tier 2 — co-IP plus localization analysis in isogenic null cell line with direct mechanistic link","pmids":["21080064"],"is_preprint":false},{"year":2014,"finding":"Compound heterozygous mutations in COG2 (a de novo frameshift c.701dup/p.Tyr234* and a missense c.1900T>G/p.Trp634Gly) cause a congenital disorder of glycosylation (CDG) with defects in both sialylation and galactosylation of glycan termini. The frameshift allele undergoes nonsense-mediated decay, and patient fibroblasts show decreased protein expression of COG2 as well as COG3 and COG4.","method":"Whole-exome sequencing (trio-based), RT-PCR of patient fibroblasts, serum transferrin isoelectrofocusing for glycosylation analysis, Western blotting for COG2/3/4 protein levels","journal":"Clinical genetics","confidence":"High","confidence_rationale":"Tier 2 — patient genetics validated by molecular and biochemical analysis of fibroblasts; links specific COG2 mutations to CDG with defined glycosylation defects","pmids":["24784932"],"is_preprint":false},{"year":2016,"finding":"CRISPR knockout of COG2 in HEK293T cells causes defects in cis/medial-Golgi glycosylation, Golgi morphology, retrograde trafficking and sorting, sialylation and fucosylation, and nearly abolished binding of Cholera toxin. COG2 KO cells showed among the most severe hypoglycosylation of LAMP2 compared to other COG subunit KOs.","method":"CRISPR/Cas9 gene editing, flow cytometry (lectin/toxin binding), Western blotting, immunofluorescence of Golgi markers, N-glycan profiling by mass spectrometry","journal":"Frontiers in cell and developmental biology","confidence":"High","confidence_rationale":"Tier 2 — complete set of isogenic CRISPR KO cell lines characterized by multiple orthogonal assays across all eight COG subunits","pmids":["27066481"],"is_preprint":false}],"current_model":"COG2 (ldlCp) is an essential subunit of the eight-subunit conserved oligomeric Golgi (COG) complex that directly binds COG1, COG3, and COG4; it localizes peripherally to the cis-Golgi in a COG1- and brefeldin A-sensitive manner, interacts with the tethering factor p115, and is required for intra-Golgi retrograde trafficking that maintains Golgi glycosyltransferase localization—loss of COG2 causes widespread defects in N-/O-linked and ceramide-linked glycosylation, sphingomyelin synthesis, and glycolipid synthesis, and biallelic COG2 mutations cause a congenital disorder of glycosylation in humans."},"narrative":{"teleology":[{"year":1994,"claim":"Identification of COG2 (LDLC/ldlCp) as a peripheral Golgi protein whose localization depends on COG1 (LDLB) established that loss of a single factor could produce pleiotropic defects in multiple medial- and trans-Golgi glycosylation pathways.","evidence":"cDNA cloning, immunofluorescence, BFA treatment, and somatic cell genetics in ldlB/ldlC CHO mutants","pmids":["7962052"],"confidence":"High","gaps":["Identity and stoichiometry of the native complex containing ldlCp were unknown","Mechanism by which COG1 controls COG2 Golgi recruitment was unresolved","Whether ldlCp function is conserved beyond CHO cells was untested"]},{"year":2002,"claim":"Biochemical purification and EM imaging revealed that COG2 is an integral subunit of an eight-subunit COG complex with a bilobed ~37-nm architecture, establishing the quaternary context in which COG2 operates.","evidence":"Co-purification, deep-etch EM, and genetic complementation of ldlB/ldlC CHO mutants","pmids":["11980916"],"confidence":"High","gaps":["Which subunit–subunit contacts hold the complex together was unknown","Atomic-resolution structure of the complex was lacking"]},{"year":2004,"claim":"Systematic binary interaction mapping showed that COG2 directly contacts COG1, COG3, and COG4, placing COG2 at a hub position within lobe A of the complex.","evidence":"In vitro translation and reciprocal co-immunoprecipitation of all eight COG subunit pairs","pmids":["15047703"],"confidence":"High","gaps":["Structural basis for these interactions was not determined","Functional consequences of disrupting individual COG2 contacts were not tested"]},{"year":2007,"claim":"Discovery that COG2 physically interacts with the vesicle-tethering factor p115 (via its HR2 domain) and that this interaction is required for Golgi ribbon reformation linked the COG complex to the broader tethering machinery and revealed cell-cycle-dependent regulation of this connection.","evidence":"Co-IP with p115 deletion mutants, Golgi morphology rescue in p115-knockdown cells, cell-cycle analysis","pmids":["17274799"],"confidence":"High","gaps":["Whether additional COG subunits contribute to p115 interaction was not addressed","Mechanism of mitotic uncoupling of the p115–COG2 interaction was unexplored"]},{"year":2010,"claim":"Studies in COG2-null cells demonstrated that COG2 is required not only for glycoprotein processing but also for sphingomyelin synthesis (via SMS1 Golgi retention) and glycolipid synthesis (via SialT1 Golgi localization), broadening the functional scope of the COG complex to lipid-linked glycosylation pathways.","evidence":"SM content measurement, SMS activity assays, GM3 quantification, SialT1 co-IP with COG1, and COG2 rescue transfection in ldlC CHO cells","pmids":["21047787","21080064"],"confidence":"High","gaps":["Whether COG2 directly contacts glycosyltransferases or acts indirectly through vesicular recycling was unresolved","Extent of lipid glycosylation defects in human patients was unknown"]},{"year":2014,"claim":"Identification of biallelic COG2 mutations in a patient with congenital disorder of glycosylation demonstrated the clinical relevance of COG2 and showed that partial loss of function destabilizes lobe A partners COG3 and COG4.","evidence":"Trio whole-exome sequencing, RT-PCR for nonsense-mediated decay, transferrin isoelectrofocusing, Western blotting of patient fibroblasts","pmids":["24784932"],"confidence":"High","gaps":["Only a single family was reported; genotype–phenotype spectrum remained narrow","Whether the missense allele retains partial complex assembly was not tested structurally"]},{"year":2016,"claim":"CRISPR knockout of all eight COG subunits in a uniform genetic background showed that COG2 loss produces among the most severe glycosylation and trafficking defects, confirming its central role in the complex and its non-redundancy with other subunits.","evidence":"CRISPR/Cas9 KO in HEK293T cells, flow cytometry with lectins/toxins, mass spectrometric N-glycan profiling, immunofluorescence","pmids":["27066481"],"confidence":"High","gaps":["High-resolution structure of COG2 within the assembled complex remains unresolved","Cargo specificity of COG-dependent retrograde vesicles is incompletely catalogued"]},{"year":null,"claim":"The structural basis of COG2's hub role—how it simultaneously engages COG1, COG3, COG4, and p115—and the precise cargo repertoire of COG2-dependent retrograde vesicles remain open questions.","evidence":"","pmids":[],"confidence":"High","gaps":["No high-resolution structure of COG2 or the lobe A sub-complex","Full inventory of Golgi enzymes dependent on COG2-mediated recycling is lacking","Therapeutic strategies for COG2-CDG have not been developed"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0060090","term_label":"molecular adaptor activity","supporting_discovery_ids":[2,4]}],"localization":[{"term_id":"GO:0005794","term_label":"Golgi apparatus","supporting_discovery_ids":[0,1,5,6,8]},{"term_id":"GO:0031410","term_label":"cytoplasmic vesicle","supporting_discovery_ids":[3,8]}],"pathway":[{"term_id":"R-HSA-5653656","term_label":"Vesicle-mediated transport","supporting_discovery_ids":[3,4,8]},{"term_id":"R-HSA-392499","term_label":"Metabolism of proteins","supporting_discovery_ids":[0,5,6,7,8]},{"term_id":"R-HSA-1430728","term_label":"Metabolism","supporting_discovery_ids":[5,6]},{"term_id":"R-HSA-1643685","term_label":"Disease","supporting_discovery_ids":[7]}],"complexes":["COG complex"],"partners":["COG1","COG3","COG4","P115","SMS1","SIALT1"],"other_free_text":[]},"mechanistic_narrative":"COG2 is a core subunit of the eight-subunit conserved oligomeric Golgi (COG) complex that functions as a peripheral membrane tethering factor essential for intra-Golgi retrograde vesicular trafficking, thereby maintaining the steady-state localization of resident Golgi glycosyltransferases and normal Golgi morphology [PMID:11980916, PMID:27066481]. Within the complex, COG2 directly binds COG1, COG3, and COG4, and its own Golgi association depends on COG1 and is sensitive to brefeldin A; COG2 also interacts with the vesicle-tethering factor p115 to promote Golgi ribbon integrity during interphase [PMID:7962052, PMID:15047703, PMID:17274799]. Loss of COG2 causes widespread defects in N-linked, O-linked, and ceramide-linked glycosylation, including mislocalization of sphingomyelin synthase SMS1 and the glycolipid sialyltransferase SialT1, leading to reduced sphingomyelin synthesis and blocked GM3 production [PMID:21047787, PMID:21080064, PMID:27066481]. Biallelic COG2 mutations cause a congenital disorder of glycosylation (CDG) characterized by impaired sialylation and galactosylation and reduced COG2/COG3/COG4 protein levels [PMID:24784932]."},"prefetch_data":{"uniprot":{"accession":"Q14746","full_name":"Conserved oligomeric Golgi complex subunit 2","aliases":["Component of oligomeric Golgi complex 2","Low density lipoprotein receptor defect C-complementing protein"],"length_aa":738,"mass_kda":83.2,"function":"Required for normal Golgi morphology and function","subcellular_location":"Golgi apparatus membrane","url":"https://www.uniprot.org/uniprotkb/Q14746/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":true,"resolved_as":"","url":"https://depmap.org/portal/gene/COG2","classification":"Common Essential","n_dependent_lines":825,"n_total_lines":1208,"dependency_fraction":0.6829470198675497},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[{"gene":"PSMA4","stoichiometry":0.2},{"gene":"RAB1B","stoichiometry":0.2}],"url":"https://opencell.sf.czbiohub.org/search/COG2","total_profiled":1310},"omim":[{"mim_id":"617395","title":"CONGENITAL DISORDER OF GLYCOSYLATION, TYPE IIq; CDG2Q","url":"https://www.omim.org/entry/617395"},{"mim_id":"617084","title":"TRANSMEMBRANE PROTEIN 59; TMEM59","url":"https://www.omim.org/entry/617084"},{"mim_id":"614638","title":"DESUMOYLATING ISOPEPTIDASE 2; DESI2","url":"https://www.omim.org/entry/614638"},{"mim_id":"608779","title":"CONGENITAL DISORDER OF GLYCOSYLATION, TYPE IIe; CDG2E","url":"https://www.omim.org/entry/608779"},{"mim_id":"606979","title":"COMPONENT OF OLIGOMERIC GOLGI COMPLEX 8; COG8","url":"https://www.omim.org/entry/606979"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Approved","locations":[{"location":"Golgi apparatus","reliability":"Approved"}],"tissue_specificity":"Tissue enhanced","tissue_distribution":"Detected in all","driving_tissues":[{"tissue":"parathyroid gland","ntpm":66.9}],"url":"https://www.proteinatlas.org/search/COG2"},"hgnc":{"alias_symbol":[],"prev_symbol":["LDLC"]},"alphafold":{"accession":"Q14746","domains":[{"cath_id":"1.10.357","chopping":"571-669_685-735","consensus_level":"high","plddt":82.691,"start":571,"end":735}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/Q14746","model_url":"https://alphafold.ebi.ac.uk/files/AF-Q14746-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-Q14746-F1-predicted_aligned_error_v6.png","plddt_mean":80.75},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=COG2","jax_strain_url":"https://www.jax.org/strain/search?query=COG2"},"sequence":{"accession":"Q14746","fasta_url":"https://rest.uniprot.org/uniprotkb/Q14746.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/Q14746/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/Q14746"}},"corpus_meta":[{"pmid":"27673306","id":"PMC_27673306","title":"Association Between Lowering LDL-C and Cardiovascular Risk Reduction Among Different Therapeutic Interventions: A Systematic Review and Meta-analysis.","date":"2016","source":"JAMA","url":"https://pubmed.ncbi.nlm.nih.gov/27673306","citation_count":1115,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"27892461","id":"PMC_27892461","title":"Liver-specific ATP-citrate lyase inhibition by bempedoic acid decreases LDL-C and attenuates atherosclerosis.","date":"2016","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/27892461","citation_count":358,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"23884353","id":"PMC_23884353","title":"AMG145, a monoclonal antibody against proprotein convertase subtilisin kexin type 9, significantly reduces lipoprotein(a) in hypercholesterolemic patients receiving statin therapy: an analysis from the LDL-C Assessment with Proprotein Convertase Subtilisin Kexin Type 9 Monoclonal Antibody Inhibition Combined with Statin Therapy (LAPLACE)-Thrombolysis in Myocardial Infarction (TIMI) 57 trial.","date":"2013","source":"Circulation","url":"https://pubmed.ncbi.nlm.nih.gov/23884353","citation_count":155,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"22368281","id":"PMC_22368281","title":"Genome-wide association study of genetic determinants of LDL-c response to atorvastatin therapy: importance of Lp(a).","date":"2012","source":"Journal of lipid research","url":"https://pubmed.ncbi.nlm.nih.gov/22368281","citation_count":95,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"9834196","id":"PMC_9834196","title":"COG-2, a sox domain protein necessary for establishing a functional vulval-uterine connection in Caenorhabditis elegans.","date":"1999","source":"Development (Cambridge, England)","url":"https://pubmed.ncbi.nlm.nih.gov/9834196","citation_count":69,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"27456066","id":"PMC_27456066","title":"Unmet Needs in LDL-C Lowering: When Statins Won't Do!","date":"2016","source":"Drugs","url":"https://pubmed.ncbi.nlm.nih.gov/27456066","citation_count":67,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"27128549","id":"PMC_27128549","title":"Association between plasma PCSK9 levels and 10-year progression of carotid atherosclerosis beyond LDL-C: A cohort study.","date":"2016","source":"International journal of cardiology","url":"https://pubmed.ncbi.nlm.nih.gov/27128549","citation_count":65,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"22451038","id":"PMC_22451038","title":"Intake levels of dietary long-chain PUFAs modify the association between genetic variation in FADS and LDL-C.","date":"2012","source":"Journal of lipid research","url":"https://pubmed.ncbi.nlm.nih.gov/22451038","citation_count":58,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"28465483","id":"PMC_28465483","title":"CRISPR/Cas9-mediated ApoE-/- and LDLR-/- double gene knockout in pigs elevates serum LDL-C and TC levels.","date":"2017","source":"Oncotarget","url":"https://pubmed.ncbi.nlm.nih.gov/28465483","citation_count":58,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"7962052","id":"PMC_7962052","title":"LDLC encodes a brefeldin A-sensitive, peripheral Golgi protein required for normal Golgi function.","date":"1994","source":"The Journal of cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/7962052","citation_count":57,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"23835245","id":"PMC_23835245","title":"Effects of icosapent ethyl on lipid and inflammatory parameters in patients with diabetes mellitus-2, residual elevated triglycerides (200-500 mg/dL), and on statin therapy at LDL-C goal: the ANCHOR study.","date":"2013","source":"Cardiovascular diabetology","url":"https://pubmed.ncbi.nlm.nih.gov/23835245","citation_count":57,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"25652089","id":"PMC_25652089","title":"Reduction of circulating PCSK9 and LDL-C levels by liver-specific knockdown of HNF1α in normolipidemic mice.","date":"2015","source":"Journal of lipid research","url":"https://pubmed.ncbi.nlm.nih.gov/25652089","citation_count":55,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"30270085","id":"PMC_30270085","title":"Clinical utility of the polygenic LDL-C SNP score in familial hypercholesterolemia.","date":"2018","source":"Atherosclerosis","url":"https://pubmed.ncbi.nlm.nih.gov/30270085","citation_count":50,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"33536384","id":"PMC_33536384","title":"High Triglyceride-Glucose Index is Associated with Poor Cardiovascular Outcomes in Nondiabetic Patients with ACS with LDL-C below 1.8 mmol/L.","date":"2021","source":"Journal of atherosclerosis and thrombosis","url":"https://pubmed.ncbi.nlm.nih.gov/33536384","citation_count":49,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"17058629","id":"PMC_17058629","title":"Ezetimibe added to ongoing statin therapy improves LDL-C goal attainment and lipid profile in patients with diabetes or metabolic syndrome.","date":"2006","source":"Diabetes & vascular disease research","url":"https://pubmed.ncbi.nlm.nih.gov/17058629","citation_count":49,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"21425956","id":"PMC_21425956","title":"Impact of SLCO1B1 (OATP1B1) and ABCG2 (BCRP) genetic polymorphisms and inhibition on LDL-C lowering and myopathy of statins.","date":"2011","source":"Xenobiotica; the fate of foreign compounds in biological systems","url":"https://pubmed.ncbi.nlm.nih.gov/21425956","citation_count":47,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"24784932","id":"PMC_24784932","title":"Mutations in COG2 encoding a subunit of the conserved oligomeric golgi complex cause a congenital disorder of glycosylation.","date":"2014","source":"Clinical genetics","url":"https://pubmed.ncbi.nlm.nih.gov/24784932","citation_count":47,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"28343601","id":"PMC_28343601","title":"Effects of RG7652, a Monoclonal Antibody Against PCSK9, on LDL-C, LDL-C Subfractions, and Inflammatory Biomarkers in Patients at High Risk of or With Established Coronary Heart Disease (from the Phase 2 EQUATOR Study).","date":"2017","source":"The American journal of cardiology","url":"https://pubmed.ncbi.nlm.nih.gov/28343601","citation_count":47,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"23172660","id":"PMC_23172660","title":"Measurement of LDL-C after treatment with the CETP inhibitor anacetrapib.","date":"2012","source":"Journal of lipid research","url":"https://pubmed.ncbi.nlm.nih.gov/23172660","citation_count":47,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"15899106","id":"PMC_15899106","title":"LDL-C goal attainment with the addition of ezetimibe to ongoing simvastatin treatment in coronary heart disease patients with hypercholesterolemia.","date":"2005","source":"Current medical research and opinion","url":"https://pubmed.ncbi.nlm.nih.gov/15899106","citation_count":40,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"23623011","id":"PMC_23623011","title":"Beyond LDL-C lowering: distinct molecular sphingolipids are good indicators of proprotein convertase subtilisin/kexin type 9 (PCSK9) deficiency.","date":"2013","source":"Atherosclerosis","url":"https://pubmed.ncbi.nlm.nih.gov/23623011","citation_count":36,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"25418907","id":"PMC_25418907","title":"A randomized, double blind, placebo-controlled pilot trial of the safety and efficacy of atorvastatin in children with elevated low-density lipoprotein cholesterol (LDL-C) and type 1 diabetes.","date":"2014","source":"Pediatric diabetes","url":"https://pubmed.ncbi.nlm.nih.gov/25418907","citation_count":35,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"30953636","id":"PMC_30953636","title":"Keep recycling going: New approaches to reduce LDL-C.","date":"2019","source":"Biochemical pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/30953636","citation_count":32,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"25201834","id":"PMC_25201834","title":"Disruption of ldlr causes increased LDL-c and vascular lipid accumulation in a zebrafish model of hypercholesterolemia.","date":"2014","source":"Journal of lipid research","url":"https://pubmed.ncbi.nlm.nih.gov/25201834","citation_count":32,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"35410491","id":"PMC_35410491","title":"Effect of Lipoprotein(a) on Stroke Recurrence Attenuates at Low LDL-C (Low-Density Lipoprotein) and Inflammation Levels.","date":"2022","source":"Stroke","url":"https://pubmed.ncbi.nlm.nih.gov/35410491","citation_count":31,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"22809019","id":"PMC_22809019","title":"Differential microRNA response to a high-cholesterol, high-fat diet in livers of low and high LDL-C baboons.","date":"2012","source":"BMC genomics","url":"https://pubmed.ncbi.nlm.nih.gov/22809019","citation_count":31,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"22497812","id":"PMC_22497812","title":"Interleukin 28B polymorphisms are the only common genetic variants associated with low-density lipoprotein cholesterol (LDL-C) in genotype-1 chronic hepatitis C and determine the association between LDL-C and treatment response.","date":"2012","source":"Journal of viral hepatitis","url":"https://pubmed.ncbi.nlm.nih.gov/22497812","citation_count":31,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"32398139","id":"PMC_32398139","title":"Beneficial impact of epigallocatechingallate on LDL-C through PCSK9/LDLR pathway by blocking HNF1α and activating FoxO3a.","date":"2020","source":"Journal of translational medicine","url":"https://pubmed.ncbi.nlm.nih.gov/32398139","citation_count":29,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"31043469","id":"PMC_31043469","title":"ApoB, small-dense LDL-C, Lp(a), LpPLA2 activity, and cognitive change.","date":"2019","source":"Neurology","url":"https://pubmed.ncbi.nlm.nih.gov/31043469","citation_count":29,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"23204297","id":"PMC_23204297","title":"A common variant highly associated with plasma VEGFA levels also contributes to the variation of both LDL-C and HDL-C.","date":"2012","source":"Journal of lipid research","url":"https://pubmed.ncbi.nlm.nih.gov/23204297","citation_count":29,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"37434791","id":"PMC_37434791","title":"Inclisiran: A New Strategy for LDL-C Lowering and Prevention of Atherosclerotic Cardiovascular Disease.","date":"2023","source":"Vascular health and risk management","url":"https://pubmed.ncbi.nlm.nih.gov/37434791","citation_count":28,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"27578130","id":"PMC_27578130","title":"Familial hypercholesterolemia/autosomal dominant hypercholesterolemia: Molecular defects, the LDL-C continuum, and gradients of phenotypic severity.","date":"2016","source":"Journal of clinical lipidology","url":"https://pubmed.ncbi.nlm.nih.gov/27578130","citation_count":28,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"32109664","id":"PMC_32109664","title":"Hsa-miR-140-5p down-regulates LDL receptor and attenuates LDL-C uptake in human hepatocytes.","date":"2020","source":"Atherosclerosis","url":"https://pubmed.ncbi.nlm.nih.gov/32109664","citation_count":26,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"27973560","id":"PMC_27973560","title":"Identification of the Functional Variant(s) that Explain the Low-Density Lipoprotein Receptor (LDLR) GWAS SNP rs6511720 Association with Lower LDL-C and Risk of CHD.","date":"2016","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/27973560","citation_count":26,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"17348840","id":"PMC_17348840","title":"Identifying and attaining LDL-C goals: mission accomplished? Next target: new therapeutic options to raise HDL-C levels.","date":"2007","source":"Current drug targets","url":"https://pubmed.ncbi.nlm.nih.gov/17348840","citation_count":25,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"16083541","id":"PMC_16083541","title":"The DISCOVERY PENTA study: a DIrect Statin COmparison of LDL-C Value--an Evaluation of Rosuvastatin therapY compared with atorvastatin.","date":"2005","source":"Current medical research and opinion","url":"https://pubmed.ncbi.nlm.nih.gov/16083541","citation_count":25,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"14559932","id":"PMC_14559932","title":"Complex multivitamin supplementation improves homocysteine and resistance to LDL-C oxidation.","date":"2003","source":"Journal of the American College of Nutrition","url":"https://pubmed.ncbi.nlm.nih.gov/14559932","citation_count":23,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"33737240","id":"PMC_33737240","title":"New PCSK9 inhibitor miR-552-3p reduces LDL-C via enhancing LDLR in high fat diet-fed mice.","date":"2021","source":"Pharmacological research","url":"https://pubmed.ncbi.nlm.nih.gov/33737240","citation_count":23,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"24899878","id":"PMC_24899878","title":"Effects of cumin extract on oxLDL, paraoxanase 1 activity, FBS, total cholesterol, triglycerides, HDL-C, LDL-C, Apo A1, and Apo B in in the patients with hypercholesterolemia.","date":"2014","source":"International journal of health sciences","url":"https://pubmed.ncbi.nlm.nih.gov/24899878","citation_count":21,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"21047787","id":"PMC_21047787","title":"Cog2 null mutant CHO cells show defective sphingomyelin synthesis.","date":"2010","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/21047787","citation_count":21,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"33775647","id":"PMC_33775647","title":"MiR-337-3p lowers serum LDL-C level through targeting PCSK9 in hyperlipidemic mice.","date":"2021","source":"Metabolism: clinical and experimental","url":"https://pubmed.ncbi.nlm.nih.gov/33775647","citation_count":20,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"18395728","id":"PMC_18395728","title":"Reduction of charge-modified LDL by statin therapy in patients with CHD or CHD risk factors and elevated LDL-C levels: the SPECIAL Study.","date":"2008","source":"Atherosclerosis","url":"https://pubmed.ncbi.nlm.nih.gov/18395728","citation_count":19,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"28673574","id":"PMC_28673574","title":"LDL-C levels in older people: Cholesterol homeostasis and the free radical theory of ageing converge.","date":"2017","source":"Medical hypotheses","url":"https://pubmed.ncbi.nlm.nih.gov/28673574","citation_count":18,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"37409534","id":"PMC_37409534","title":"Prevalence of FH-Causing Variants and Impact on LDL-C Concentration in European, South Asian, and African Ancestry Groups of the UK Biobank-Brief Report.","date":"2023","source":"Arteriosclerosis, thrombosis, and vascular biology","url":"https://pubmed.ncbi.nlm.nih.gov/37409534","citation_count":17,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"10686277","id":"PMC_10686277","title":"Prebeta1-high-density lipoprotein (prebeta1-HDL) concentration can change with low-density lipoprotein-cholesterol (LDL-C) concentration independent of cholesteryl ester transfer protein (CETP).","date":"2000","source":"Clinica chimica acta; international journal of clinical chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/10686277","citation_count":17,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"31708410","id":"PMC_31708410","title":"Relationship between alirocumab, PCSK9, and LDL-C levels in four phase 3 ODYSSEY trials using 75 and 150 mg doses.","date":"2019","source":"Journal of clinical lipidology","url":"https://pubmed.ncbi.nlm.nih.gov/31708410","citation_count":17,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"38216056","id":"PMC_38216056","title":"VXX-401, a novel anti-PCSK9 vaccine, reduces LDL-C in cynomolgus monkeys.","date":"2024","source":"Journal of lipid research","url":"https://pubmed.ncbi.nlm.nih.gov/38216056","citation_count":17,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"30657354","id":"PMC_30657354","title":"Different susceptibility to fatty liver-haemorrhagic syndrome in young and older layers and the interaction on blood LDL-C levels between oestradiols and high energy-low protein diets.","date":"2019","source":"British poultry science","url":"https://pubmed.ncbi.nlm.nih.gov/30657354","citation_count":17,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"26415676","id":"PMC_26415676","title":"Next-generation-sequencing-based identification of familial hypercholesterolemia-related mutations in subjects with increased LDL-C levels in a latvian population.","date":"2015","source":"BMC medical genetics","url":"https://pubmed.ncbi.nlm.nih.gov/26415676","citation_count":17,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"27112212","id":"PMC_27112212","title":"Effect of SORT1, APOB and APOE polymorphisms on LDL-C and coronary heart disease in Pakistani subjects and their comparison with Northwick Park Heart Study II.","date":"2016","source":"Lipids in health and disease","url":"https://pubmed.ncbi.nlm.nih.gov/27112212","citation_count":16,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"36680595","id":"PMC_36680595","title":"COG2 negatively regulates chilling tolerance through cell wall components altered in rice.","date":"2023","source":"TAG. Theoretical and applied genetics. Theoretische und angewandte Genetik","url":"https://pubmed.ncbi.nlm.nih.gov/36680595","citation_count":15,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"32463301","id":"PMC_32463301","title":"Bempedoic acid: a promising novel agent for LDL-C lowering.","date":"2020","source":"Future cardiology","url":"https://pubmed.ncbi.nlm.nih.gov/32463301","citation_count":15,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"39679827","id":"PMC_39679827","title":"Current and emerging PCSK9-directed therapies to reduce LDL-C and ASCVD risk: A state-of-the-art review.","date":"2024","source":"Pharmacotherapy","url":"https://pubmed.ncbi.nlm.nih.gov/39679827","citation_count":14,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"23305113","id":"PMC_23305113","title":"The combined effects of genetic variation in the SIRT1 gene and dietary intake of n-3 and n-6 polyunsaturated fatty acids on serum LDL-C and HDL-C levels: a population based study.","date":"2013","source":"Lipids in health and disease","url":"https://pubmed.ncbi.nlm.nih.gov/23305113","citation_count":14,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"22109348","id":"PMC_22109348","title":"A review of the rationale for additional therapeutic interventions to attain lower LDL-C when statin therapy is not enough.","date":"2012","source":"Current atherosclerosis reports","url":"https://pubmed.ncbi.nlm.nih.gov/22109348","citation_count":14,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"21080064","id":"PMC_21080064","title":"Defective GM3 synthesis in Cog2 null mutant CHO cells associates to mislocalization of lactosylceramide sialyltransferase in the Golgi complex.","date":"2010","source":"Neurochemical research","url":"https://pubmed.ncbi.nlm.nih.gov/21080064","citation_count":13,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"38636099","id":"PMC_38636099","title":"LDL-C and TC Mediate the Risk of PNPLA3 Inhibition in Cardiovascular Diseases.","date":"2025","source":"The Journal of clinical endocrinology and metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/38636099","citation_count":13,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"32056048","id":"PMC_32056048","title":"The novel llama-human chimeric antibody has potent effect in lowering LDL-c levels in hPCSK9 transgenic rats.","date":"2020","source":"Clinical and translational medicine","url":"https://pubmed.ncbi.nlm.nih.gov/32056048","citation_count":13,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"32544081","id":"PMC_32544081","title":"The impact of the cumulative burden of LDL-c and hs-CRP on cardiovascular risk: a prospective, population-based study.","date":"2020","source":"Aging","url":"https://pubmed.ncbi.nlm.nih.gov/32544081","citation_count":13,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"34865983","id":"PMC_34865983","title":"LDL-C augments whereas HDL-C prevents inflammatory innate immune memory.","date":"2021","source":"Trends in molecular medicine","url":"https://pubmed.ncbi.nlm.nih.gov/34865983","citation_count":13,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"35123856","id":"PMC_35123856","title":"The role of adiposity, diet and inflammation on the discordance between LDL-C and apolipoprotein B.","date":"2021","source":"Nutrition, metabolism, and cardiovascular diseases : NMCD","url":"https://pubmed.ncbi.nlm.nih.gov/35123856","citation_count":12,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"29747696","id":"PMC_29747696","title":"Oxidative modifications of foetal LDL-c and HDL-c lipoproteins in preeclampsia.","date":"2018","source":"Lipids in health and disease","url":"https://pubmed.ncbi.nlm.nih.gov/29747696","citation_count":12,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"25601895","id":"PMC_25601895","title":"Elevated Levels of LDL-C are Associated With ApoE4 but Not With the rs688 Polymorphism in the LDLR Gene.","date":"2015","source":"Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis","url":"https://pubmed.ncbi.nlm.nih.gov/25601895","citation_count":12,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"37482217","id":"PMC_37482217","title":"Reducing saturated fat intake lowers LDL-C but increases Lp(a) levels in African Americans: the GET-READI feeding trial.","date":"2023","source":"Journal of lipid research","url":"https://pubmed.ncbi.nlm.nih.gov/37482217","citation_count":12,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"28941386","id":"PMC_28941386","title":"Trp64Arg polymorphism of the ADRB3 gene associated with maximal fat oxidation and LDL-C levels in non-obese adolescents.","date":"2017","source":"Jornal de pediatria","url":"https://pubmed.ncbi.nlm.nih.gov/28941386","citation_count":12,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"23596326","id":"PMC_23596326","title":"Identification of candidate genes encoding an LDL-C QTL in baboons.","date":"2013","source":"Journal of lipid research","url":"https://pubmed.ncbi.nlm.nih.gov/23596326","citation_count":12,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"35956226","id":"PMC_35956226","title":"Newer and Emerging LDL-C Lowering Agents and Implications for ASCVD Residual Risk.","date":"2022","source":"Journal of clinical medicine","url":"https://pubmed.ncbi.nlm.nih.gov/35956226","citation_count":11,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"35036030","id":"PMC_35036030","title":"Expanded IL-22+ Group 3 Innate Lymphoid Cells and Role of Oxidized LDL-C in the Pathogenesis of Axial Spondyloarthritis with Dyslipidaemia.","date":"2021","source":"Immune network","url":"https://pubmed.ncbi.nlm.nih.gov/35036030","citation_count":11,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"26984517","id":"PMC_26984517","title":"Serum CETP status is independently associated with reduction rates in LDL-C in pitavastatin-treated diabetic patients and possible involvement of LXR in its association.","date":"2016","source":"Lipids in health and disease","url":"https://pubmed.ncbi.nlm.nih.gov/26984517","citation_count":11,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"31957803","id":"PMC_31957803","title":"SULT2B1b inhibits reverse cholesterol transport and promotes cholesterol accumulation and inflammation in lymphocytes from AMI patients with low LDL-C levels.","date":"2020","source":"Clinical science (London, England : 1979)","url":"https://pubmed.ncbi.nlm.nih.gov/31957803","citation_count":11,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"30641698","id":"PMC_30641698","title":"Beyond LDL-c: The importance of serum oxidized LDL in predicting risk for type 2 diabetes in the middle-aged Asian Indians.","date":"2018","source":"Diabetes & metabolic syndrome","url":"https://pubmed.ncbi.nlm.nih.gov/30641698","citation_count":11,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"21291777","id":"PMC_21291777","title":"Ezetimibe/simvastatin compared with atorvastatin or rosuvastatin in lowering to specified levels both LDL-C and each of five other emerging risk factors for coronary heart disease: Non-HDL-cholesterol, TC/HDL-C, apolipoprotein B, apo-B/apo-A-I, or C-reactive protein.","date":"2008","source":"Journal of clinical lipidology","url":"https://pubmed.ncbi.nlm.nih.gov/21291777","citation_count":11,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"33326437","id":"PMC_33326437","title":"The direct correlation between oxidative stress and LDL-C levels in adults is maintained by the Friedewald and Martin equations, but the methylation levels in the MTHFR and ADRB3 genes differ.","date":"2020","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/33326437","citation_count":10,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"21090831","id":"PMC_21090831","title":"Rosuvastatin: a review of its use in the prevention of cardiovascular disease in apparently healthy women or men with normal LDL-C levels and elevated hsCRP levels.","date":"2010","source":"American journal of cardiovascular drugs : drugs, devices, and other interventions","url":"https://pubmed.ncbi.nlm.nih.gov/21090831","citation_count":10,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"19122109","id":"PMC_19122109","title":"Jupiter to earth: a statin helps people with normal LDL-C and high hs-CRP, but what does it mean?","date":"2009","source":"Cleveland Clinic journal of medicine","url":"https://pubmed.ncbi.nlm.nih.gov/19122109","citation_count":10,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"34393074","id":"PMC_34393074","title":"Greater than expected reduction in low-density lipoprotein-cholesterol (LDL-C) with bempedoic acid in a patient with heterozygous familial hypercholesterolemia (HeFH).","date":"2021","source":"Journal of clinical lipidology","url":"https://pubmed.ncbi.nlm.nih.gov/34393074","citation_count":10,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"23607609","id":"PMC_23607609","title":"The effects of phytosterol supplementation on serum LDL-C levels and learning ability in mice fed a high-fat, high-energy diet from gestation onward.","date":"2013","source":"International journal of food sciences and nutrition","url":"https://pubmed.ncbi.nlm.nih.gov/23607609","citation_count":9,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"36082889","id":"PMC_36082889","title":"Unmet Need for Further LDL-C Lowering in India despite Statin Therapy: Lipid Association of India Recommendations for the Use of Bempedoic Acid.","date":"2022","source":"The Journal of the Association of Physicians of India","url":"https://pubmed.ncbi.nlm.nih.gov/36082889","citation_count":9,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"27483697","id":"PMC_27483697","title":"NEW CLASS OF DRUGS: THERAPEUTIC RNAi INHIBITION OF PCSK9 AS A SPECIFIC LDL-C LOWERING THERAPY.","date":"2016","source":"Revista medico-chirurgicala a Societatii de Medici si Naturalisti din Iasi","url":"https://pubmed.ncbi.nlm.nih.gov/27483697","citation_count":9,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"39516755","id":"PMC_39516755","title":"Association analysis of gut microbiota with LDL-C metabolism and microbial pathogenicity in colorectal cancer patients.","date":"2024","source":"Lipids in health and disease","url":"https://pubmed.ncbi.nlm.nih.gov/39516755","citation_count":8,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"25466164","id":"PMC_25466164","title":"High levels of LDL-C combined with low levels of HDL-C further increase platelet activation in hypercholesterolemic patients.","date":"2014","source":"Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologicas","url":"https://pubmed.ncbi.nlm.nih.gov/25466164","citation_count":8,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"21291712","id":"PMC_21291712","title":"Effect of ezetimibe/simvastatin vs atorvastatin on lowering levels of LDL-C and non-HDL-C, ApoB, and hs-CRP in patients with type 2 diabetes.","date":"2008","source":"Journal of clinical lipidology","url":"https://pubmed.ncbi.nlm.nih.gov/21291712","citation_count":8,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"31574854","id":"PMC_31574854","title":"Association of rs2000999 in the haptoglobin gene with total cholesterol, HDL-C, and LDL-C levels in Mexican type 2 diabetes patients.","date":"2019","source":"Medicine","url":"https://pubmed.ncbi.nlm.nih.gov/31574854","citation_count":7,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"31731717","id":"PMC_31731717","title":"Lunasin Improves the LDL-C Lowering Efficacy of Simvastatin via Inhibiting PCSK9 Expression in Hepatocytes and ApoE-/- Mice.","date":"2019","source":"Molecules (Basel, Switzerland)","url":"https://pubmed.ncbi.nlm.nih.gov/31731717","citation_count":7,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"32929056","id":"PMC_32929056","title":"Ineffective Subtilisin/Kexin Type 9 (PCSK9) Inhibitors Monotherapy in Dyslipidemia with Low-Density Lipoprotein Cholesterol (LDL-C) Receptor Abnormalities: A Report of 2 Cases.","date":"2020","source":"The American journal of case reports","url":"https://pubmed.ncbi.nlm.nih.gov/32929056","citation_count":7,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"38169062","id":"PMC_38169062","title":"The Effect of PCSK9 Inhibitors on LDL-C Target Achievement in Patients with Homozygous Familial Hypercholesterolemia: A Retrospective Cohort Analysis.","date":"2024","source":"Advances in therapy","url":"https://pubmed.ncbi.nlm.nih.gov/38169062","citation_count":7,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"37417318","id":"PMC_37417318","title":"Filling the gap: Genetic risk assessment in hypercholesterolemia using LDL-C and LPA genetic scores.","date":"2023","source":"Clinical genetics","url":"https://pubmed.ncbi.nlm.nih.gov/37417318","citation_count":6,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"35174858","id":"PMC_35174858","title":"Modifying pH-sensitive PCSK9/LDLR interactions as a strategy to enhance hepatic cell uptake of low-density lipoprotein cholesterol (LDL-C).","date":"2022","source":"Protein engineering, design & selection : PEDS","url":"https://pubmed.ncbi.nlm.nih.gov/35174858","citation_count":6,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"38365720","id":"PMC_38365720","title":"A regulatory element associated to NAFLD in the promoter of DIO1 controls LDL-C, HDL-C and triglycerides in hepatic cells.","date":"2024","source":"Lipids in health and disease","url":"https://pubmed.ncbi.nlm.nih.gov/38365720","citation_count":6,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"35432461","id":"PMC_35432461","title":"LDL-C Concentrations and the 12-SNP LDL-C Score for Polygenic Hypercholesterolaemia in Self-Reported South Asian, Black and Caribbean Participants of the UK Biobank.","date":"2022","source":"Frontiers in genetics","url":"https://pubmed.ncbi.nlm.nih.gov/35432461","citation_count":6,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"39694503","id":"PMC_39694503","title":"Effects of Pemafibrate on LDL-C and Related Lipid Markers in Patients with MASLD: A Sub-Analysis of the PEMA-FL Study.","date":"2024","source":"Journal of atherosclerosis and thrombosis","url":"https://pubmed.ncbi.nlm.nih.gov/39694503","citation_count":5,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"40409246","id":"PMC_40409246","title":"Beneficial changes in total cholesterol, LDL-C, biomarkers of intestinal inflammation, and vitamin E status in adults with metabolic syndrome consuming almonds as snack foods: a randomized controlled clinical trial.","date":"2025","source":"Nutrition research (New York, N.Y.)","url":"https://pubmed.ncbi.nlm.nih.gov/40409246","citation_count":5,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"21752895","id":"PMC_21752895","title":"Variants in STAT5B associate with serum TC and LDL-C levels.","date":"2011","source":"The Journal of clinical endocrinology and metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/21752895","citation_count":5,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"10404285","id":"PMC_10404285","title":"Elevated low-density lipoprotein cholesterol (LDL-C) enhances pro-erectile neurotransmission in the corpus cavernosum.","date":"1999","source":"International journal of impotence research","url":"https://pubmed.ncbi.nlm.nih.gov/10404285","citation_count":5,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"8891379","id":"PMC_8891379","title":"Genetic contributions to LDL-C, Apo-B and LDL-C/Apo-B ratio in a sample of Israeli offspring with a parental history of myocardial infarction.","date":"1996","source":"Clinical genetics","url":"https://pubmed.ncbi.nlm.nih.gov/8891379","citation_count":4,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"38735347","id":"PMC_38735347","title":"Evolution of LDL-C lowering medications and their cardiovascular benefits: Past, present, and future.","date":"2024","source":"Current problems in cardiology","url":"https://pubmed.ncbi.nlm.nih.gov/38735347","citation_count":4,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"35363365","id":"PMC_35363365","title":"PPARα polymorphisms association with total cholesterol and LDL-C levels in a Mexican population.","date":"2022","source":"European review for medical and pharmacological sciences","url":"https://pubmed.ncbi.nlm.nih.gov/35363365","citation_count":4,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"37913995","id":"PMC_37913995","title":"Missense variants in SORT1 are associated with LDL-C in an Amish population.","date":"2023","source":"Journal of lipid research","url":"https://pubmed.ncbi.nlm.nih.gov/37913995","citation_count":4,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"35013023","id":"PMC_35013023","title":"The Contribution of Inflammation to Stroke Recurrence Attenuates at Low LDL-C Levels.","date":"2022","source":"Journal of atherosclerosis and thrombosis","url":"https://pubmed.ncbi.nlm.nih.gov/35013023","citation_count":4,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"35800677","id":"PMC_35800677","title":"Effects of Serum LDL-C, CysC, and D-D in Patients with Coronary Atherosclerotic Heart Disease.","date":"2022","source":"Computational intelligence and neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/35800677","citation_count":3,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"12477932","id":"PMC_12477932","title":"Generation and initial analysis of more than 15,000 full-length human and mouse cDNA sequences.","date":"2002","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/12477932","citation_count":1479,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"18187620","id":"PMC_18187620","title":"Identification of host proteins required for HIV infection through a functional genomic screen.","date":"2008","source":"Science (New York, N.Y.)","url":"https://pubmed.ncbi.nlm.nih.gov/18187620","citation_count":1165,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"26186194","id":"PMC_26186194","title":"The BioPlex Network: A Systematic Exploration of the Human Interactome.","date":"2015","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/26186194","citation_count":1118,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"28514442","id":"PMC_28514442","title":"Architecture of the human interactome defines protein communities and disease networks.","date":"2017","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/28514442","citation_count":1085,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"26496610","id":"PMC_26496610","title":"A human interactome in three quantitative dimensions organized by stoichiometries and abundances.","date":"2015","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/26496610","citation_count":1015,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"25416956","id":"PMC_25416956","title":"A proteome-scale map of the human interactome network.","date":"2014","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/25416956","citation_count":977,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"32296183","id":"PMC_32296183","title":"A reference map of the human binary protein interactome.","date":"2020","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/32296183","citation_count":849,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"33961781","id":"PMC_33961781","title":"Dual proteome-scale networks reveal cell-specific remodeling of the human interactome.","date":"2021","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/33961781","citation_count":705,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"22939629","id":"PMC_22939629","title":"A census of human soluble protein complexes.","date":"2012","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/22939629","citation_count":689,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"21873635","id":"PMC_21873635","title":"Phylogenetic-based propagation of functional annotations within the Gene Ontology consortium.","date":"2011","source":"Briefings in bioinformatics","url":"https://pubmed.ncbi.nlm.nih.gov/21873635","citation_count":656,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"33845483","id":"PMC_33845483","title":"Multilevel proteomics reveals host perturbations by SARS-CoV-2 and SARS-CoV.","date":"2021","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/33845483","citation_count":532,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"15489334","id":"PMC_15489334","title":"The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC).","date":"2004","source":"Genome research","url":"https://pubmed.ncbi.nlm.nih.gov/15489334","citation_count":438,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"35271311","id":"PMC_35271311","title":"OpenCell: Endogenous tagging for the cartography of human cellular organization.","date":"2022","source":"Science (New York, N.Y.)","url":"https://pubmed.ncbi.nlm.nih.gov/35271311","citation_count":432,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"26344197","id":"PMC_26344197","title":"Panorama of ancient metazoan macromolecular complexes.","date":"2015","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/26344197","citation_count":407,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"34079125","id":"PMC_34079125","title":"A proximity-dependent biotinylation map of a human cell.","date":"2021","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/34079125","citation_count":339,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"11980916","id":"PMC_11980916","title":"Characterization of a mammalian Golgi-localized protein complex, COG, that is required for normal Golgi morphology and function.","date":"2002","source":"The Journal of cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/11980916","citation_count":238,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"30833792","id":"PMC_30833792","title":"A protein-interaction network of interferon-stimulated genes extends the innate immune system landscape.","date":"2019","source":"Nature immunology","url":"https://pubmed.ncbi.nlm.nih.gov/30833792","citation_count":159,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"17975119","id":"PMC_17975119","title":"Association of gene variants with incident myocardial infarction in the Cardiovascular Health Study.","date":"2007","source":"Arteriosclerosis, thrombosis, and vascular biology","url":"https://pubmed.ncbi.nlm.nih.gov/17975119","citation_count":142,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"16406524","id":"PMC_16406524","title":"Retrograde transport on the COG railway.","date":"2006","source":"Trends in cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/16406524","citation_count":114,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"34349018","id":"PMC_34349018","title":"Protein interaction landscapes revealed by advanced in vivo cross-linking-mass spectrometry.","date":"2021","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/34349018","citation_count":113,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"32694731","id":"PMC_32694731","title":"Systematic mapping of genetic interactions for de novo fatty acid synthesis identifies C12orf49 as a regulator of lipid metabolism.","date":"2020","source":"Nature metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/32694731","citation_count":92,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"35831314","id":"PMC_35831314","title":"Scalable multiplex co-fractionation/mass spectrometry platform for accelerated protein interactome discovery.","date":"2022","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/35831314","citation_count":65,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"17274799","id":"PMC_17274799","title":"The interaction of two tethering factors, p115 and COG complex, is required for Golgi integrity.","date":"2007","source":"Traffic (Copenhagen, Denmark)","url":"https://pubmed.ncbi.nlm.nih.gov/17274799","citation_count":63,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"25921289","id":"PMC_25921289","title":"Temporal proteomics of NGF-TrkA signaling identifies an inhibitory role for the E3 ligase Cbl-b in neuroblastoma cell differentiation.","date":"2015","source":"Science signaling","url":"https://pubmed.ncbi.nlm.nih.gov/25921289","citation_count":61,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"31515488","id":"PMC_31515488","title":"Extensive disruption of protein interactions by genetic variants across the allele frequency spectrum in human populations.","date":"2019","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/31515488","citation_count":60,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"27066481","id":"PMC_27066481","title":"COG Complex Complexities: Detailed Characterization of a Complete Set of HEK293T Cells Lacking Individual COG Subunits.","date":"2016","source":"Frontiers in cell and developmental biology","url":"https://pubmed.ncbi.nlm.nih.gov/27066481","citation_count":55,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"15047703","id":"PMC_15047703","title":"The binary interacting network of the conserved oligomeric Golgi tethering complex.","date":"2004","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/15047703","citation_count":50,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"31091453","id":"PMC_31091453","title":"PLEKHA4/kramer Attenuates Dishevelled Ubiquitination to Modulate Wnt and Planar Cell Polarity Signaling.","date":"2019","source":"Cell reports","url":"https://pubmed.ncbi.nlm.nih.gov/31091453","citation_count":42,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"19023099","id":"PMC_19023099","title":"Gene variants associated with ischemic stroke: the cardiovascular health study.","date":"2008","source":"Stroke","url":"https://pubmed.ncbi.nlm.nih.gov/19023099","citation_count":39,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"34597346","id":"PMC_34597346","title":"The proximal proteome of 17 SARS-CoV-2 proteins links to disrupted antiviral signaling and host translation.","date":"2021","source":"PLoS pathogens","url":"https://pubmed.ncbi.nlm.nih.gov/34597346","citation_count":37,"is_preprint":false,"source_track":"gene2pubmed"}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":58722,"output_tokens":1305,"usd":0.09787},"stage2":{"model":"claude-opus-4-6","input_tokens":4510,"output_tokens":1514,"usd":0.0906},"total_usd":0.444541,"stage1_batch_id":"msgbatch_011kfMfE81o6CTcyhVUqumuW","stage2_batch_id":"msgbatch_01DTputS6WNkH745x1nVSoBo","note":"batch pricing = 50% of standard","round2_stage1":{"model":"claude-sonnet-4-6","input_tokens":70959,"output_tokens":2549,"usd":0.125556},"round2_rules_fired":"R3","round2_stage2":{"model":"claude-opus-4-6","input_tokens":6087,"output_tokens":2263,"usd":0.130515}},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 2014,\n      \"finding\": \"Compound heterozygous mutations in COG2 (a frameshift c.701dup causing mRNA degradation and a missense c.1900T>G p.Trp634Gly) cause a congenital disorder of glycosylation (CDG) with defects in both sialylation and galactosylation of glycan termini. Protein expression of COG2, along with COG3 and COG4, was decreased in patient fibroblasts, establishing COG2 as required for normal Golgi glycosylation.\",\n      \"method\": \"Trio-based whole-exome sequencing, RT-PCR cloning, western blot analysis of patient fibroblasts, serum glycoprotein analysis\",\n      \"journal\": \"Clinical genetics\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — patient-derived loss-of-function with multiple orthogonal molecular methods (sequencing, RT-PCR, western blot, glycan analysis)\",\n      \"pmids\": [\"24784932\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1994,\n      \"finding\": \"LDLC (COG2) encodes a peripheral Golgi protein (~83 kD) whose association with the Golgi is brefeldin A-sensitive and depends on the LDLB (COG1) subunit. Loss of ldlCp results in pleiotropic defects in N-linked, O-linked, and ceramide-linked oligosaccharide synthesis, establishing COG2 as required for multiple Golgi functions. In ldlB cells, ldlCp is expressed at normal levels but fails to associate with the Golgi, indicating COG1-dependent Golgi recruitment of COG2.\",\n      \"method\": \"Somatic cell genetics (cDNA complementation of ldlC CHO mutants), immunofluorescence with anti-ldlCp antibodies, brefeldin A treatment, cDNA cloning and sequencing\",\n      \"journal\": \"The Journal of cell biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 — reconstitution by cDNA complementation plus direct localization experiments with functional consequences, foundational paper\",\n      \"pmids\": [\"7962052\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"In Cog2-null (ldlC) CHO cells, sphingomyelin (SM) content is reduced to ~25% of wild-type. Sphingomyelin synthase 1 (SMS1) mislocalizes from the Golgi to scattered cytoplasmic vesicles, and endogenous ceramide accumulates 3-fold, indicating that COG2 is required for proper delivery of ceramide to sites of SM synthesis. Transfection of Cog2 restores SM formation and SMS1 Golgi localization.\",\n      \"method\": \"Lipid biochemistry (SM quantification), fluorescence microscopy of transfected SMS1, exogenous C6-NBD-ceramide feeding assay, ceramide mass measurement, Cog2 rescue transfection\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 — multiple orthogonal assays plus genetic rescue in a defined null mutant cell line\",\n      \"pmids\": [\"21047787\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"In Cog2-null (ldlC) CHO cells, GM3 ganglioside synthesis is blocked at the LacCer→GM3 step due to mislocalization of lactosylceramide sialyltransferase (SialT1/ST3Gal5) away from the Golgi. Co-immunoprecipitation experiments revealed a COG2-mediated interaction between SialT1 and COG complex member COG1, indicating COG2 facilitates retention/cycling of this glycolipid glycosyltransferase within the Golgi.\",\n      \"method\": \"Biochemical glycolipid analysis, immunocytochemistry, co-immunoprecipitation of SialT1 with COG1 in COG2-dependent manner\",\n      \"journal\": \"Neurochemical research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — reciprocal co-IP plus localization and biochemical readout in defined null mutant\",\n      \"pmids\": [\"21080064\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"COG2 (ldlCp) is a peripheral subunit of the conserved oligomeric Golgi (COG) tethering complex whose Golgi association requires COG1 and is brefeldin A-sensitive; it mediates intra-Golgi retrograde trafficking of glycosylation and glycolipid-synthesizing enzymes (including SMS1 and SialT1), thereby maintaining proper N-glycosylation, O-glycosylation, sphingomyelin synthesis, and ganglioside (GM3) synthesis, and loss-of-function mutations cause congenital disorders of glycosylation.\"\n}\n```\n\n--- ROUND 2 (R2/R3, augmented corpus) ---\n\n```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 1994,\n      \"finding\": \"The LDLC protein (now known as COG2/ldlCp) is a peripheral Golgi protein (~83 kDa) whose association with the Golgi is brefeldin A-sensitive. In ldlB cells, ldlCp is expressed at normal levels but is not associated with the Golgi, indicating that its Golgi localization is LDLB (COG1)-dependent. Loss of ldlCp causes pleiotropic defects in multiple medial and trans Golgi-associated processes, including abnormal N- and O-linked glycoprotein synthesis.\",\n      \"method\": \"cDNA cloning, immunofluorescence with anti-ldlCp antibodies, brefeldin A treatment, somatic cell genetics with ldlB/ldlC CHO mutants\",\n      \"journal\": \"The Journal of cell biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — original cloning and localization study with multiple orthogonal methods (cDNA complementation, immunofluorescence, BFA treatment, cross-cell-line analysis)\",\n      \"pmids\": [\"7962052\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2002,\n      \"finding\": \"COG2 (ldlCp) is a core subunit of the conserved oligomeric Golgi (COG) complex, which also contains COG1/ldlBp, COG3/Sec34, COG4, COG5/GTC-90, COG6, COG7, and COG8. The COG complex is required for normal Golgi morphology; EM of ldlB and ldlC mutants showed Golgi structural defects. Purified COG complex revealed an ~37-nm structure with two globular domains connected by smaller extensions.\",\n      \"method\": \"Biochemical co-purification, EM (conventional and deep-etch), genetic complementation of ldlB/ldlC CHO mutants, homology analysis\",\n      \"journal\": \"The Journal of cell biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — complex reconstitution/purification, structural EM, and genetic validation across multiple subunits in the same study\",\n      \"pmids\": [\"11980916\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2004,\n      \"finding\": \"Within the COG complex, COG2 directly interacts with COG1, COG3, and COG4 as determined by in vitro translation and co-immunoprecipitation. COG4 serves as a core component interacting with COG1, COG2, COG5, and COG7; COG3 is incorporated via direct interaction with COG1 and COG2.\",\n      \"method\": \"In vitro translation, co-immunoprecipitation of individual COG subunit pairs\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — systematic binary interaction mapping by reciprocal co-IP covering all eight subunits\",\n      \"pmids\": [\"15047703\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"COG complex (including COG2) functions in retrograde vesicular trafficking within the Golgi apparatus. COG mutations impair the retrograde flow of resident Golgi proteins needed to maintain normal Golgi structure and function, explaining defects in glycoprotein modification.\",\n      \"method\": \"Review/synthesis integrating yeast, worm, fly, and mammalian genetic and cell biological data; pathway epistasis\",\n      \"journal\": \"Trends in cell biology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2-3 — model based on synthesis of genetic and trafficking data across organisms; no single direct experiment in this review paper but reflects consensus from multiple labs\",\n      \"pmids\": [\"16406524\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"COG2 interacts directly with the vesicle-tethering protein p115 (via the HR2 domain of p115). This p115–COG2 interaction is required for Golgi ribbon reformation after disruption by p115 knockdown or brefeldin A treatment; the interaction occurs only in interphase cells and not in mitotic cells.\",\n      \"method\": \"Co-immunoprecipitation, p115 deletion mutant expression in p115-knockdown cells, Golgi morphology rescue assays, cell-cycle analysis\",\n      \"journal\": \"Traffic (Copenhagen, Denmark)\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — reciprocal co-IP with deletion mapping, functional rescue of Golgi morphology, and cell-cycle specificity demonstrated in same study\",\n      \"pmids\": [\"17274799\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"In Cog2-null (ldlC) CHO cells, sphingomyelin (SM) content is reduced to ~25% of wild-type. Sphingomyelin synthase (SMS1) is mislocalized from the Golgi to vesicular cytoplasmic structures in ldlC cells, and ceramide levels are 3-fold elevated, indicating that COG2 is required for proper delivery of ceramide to SMS1 at the Golgi for SM synthesis. Transfection of COG2 rescues SM levels and SMS1 Golgi localization.\",\n      \"method\": \"SM content measurement, SMS activity assays, fluorescence microscopy of transfected SMS1 and CERT, exogenous C6-NBD-ceramide assay, COG2 rescue transfection in ldlC cells\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — multiple orthogonal biochemical and cell biological assays including genetic rescue in Cog2-null cells\",\n      \"pmids\": [\"21047787\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"In Cog2-null (ldlC) CHO cells, GM3 synthesis is specifically blocked due to mislocalization of the lactosylceramide sialyltransferase SialT1 from the Golgi. Co-immunoprecipitation revealed a COG2-mediated interaction between SialT1 and the COG complex subunit COG1, indicating COG2 is required for proper Golgi cycling of glycolipid glycosyltransferases.\",\n      \"method\": \"Biochemical GM3 quantification, SialT1 enzyme activity assays, immunocytochemistry of SialT1 localization, co-immunoprecipitation of SialT1 with COG1\",\n      \"journal\": \"Neurochemical research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — co-IP plus localization analysis in isogenic null cell line with direct mechanistic link\",\n      \"pmids\": [\"21080064\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"Compound heterozygous mutations in COG2 (a de novo frameshift c.701dup/p.Tyr234* and a missense c.1900T>G/p.Trp634Gly) cause a congenital disorder of glycosylation (CDG) with defects in both sialylation and galactosylation of glycan termini. The frameshift allele undergoes nonsense-mediated decay, and patient fibroblasts show decreased protein expression of COG2 as well as COG3 and COG4.\",\n      \"method\": \"Whole-exome sequencing (trio-based), RT-PCR of patient fibroblasts, serum transferrin isoelectrofocusing for glycosylation analysis, Western blotting for COG2/3/4 protein levels\",\n      \"journal\": \"Clinical genetics\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — patient genetics validated by molecular and biochemical analysis of fibroblasts; links specific COG2 mutations to CDG with defined glycosylation defects\",\n      \"pmids\": [\"24784932\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"CRISPR knockout of COG2 in HEK293T cells causes defects in cis/medial-Golgi glycosylation, Golgi morphology, retrograde trafficking and sorting, sialylation and fucosylation, and nearly abolished binding of Cholera toxin. COG2 KO cells showed among the most severe hypoglycosylation of LAMP2 compared to other COG subunit KOs.\",\n      \"method\": \"CRISPR/Cas9 gene editing, flow cytometry (lectin/toxin binding), Western blotting, immunofluorescence of Golgi markers, N-glycan profiling by mass spectrometry\",\n      \"journal\": \"Frontiers in cell and developmental biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — complete set of isogenic CRISPR KO cell lines characterized by multiple orthogonal assays across all eight COG subunits\",\n      \"pmids\": [\"27066481\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"COG2 (ldlCp) is an essential subunit of the eight-subunit conserved oligomeric Golgi (COG) complex that directly binds COG1, COG3, and COG4; it localizes peripherally to the cis-Golgi in a COG1- and brefeldin A-sensitive manner, interacts with the tethering factor p115, and is required for intra-Golgi retrograde trafficking that maintains Golgi glycosyltransferase localization—loss of COG2 causes widespread defects in N-/O-linked and ceramide-linked glycosylation, sphingomyelin synthesis, and glycolipid synthesis, and biallelic COG2 mutations cause a congenital disorder of glycosylation in humans.\"\n}\n```","stage2_raw":"```json\n{\n  \"mechanistic_narrative\": \"COG2 is a peripheral subunit of the conserved oligomeric Golgi (COG) tethering complex that maintains intra-Golgi retrograde trafficking of glycosylation and glycolipid-synthesizing enzymes. Its Golgi association is brefeldin A-sensitive and depends on COG1; in COG1-deficient cells, COG2 is expressed at normal levels but fails to localize to the Golgi, establishing a hierarchical recruitment mechanism [PMID:7962052]. Loss of COG2 causes mislocalization of sphingomyelin synthase 1 (SMS1) and lactosylceramide sialyltransferase (SialT1) from the Golgi to cytoplasmic vesicles, resulting in defective sphingomyelin synthesis, blocked GM3 ganglioside production, and pleiotropic impairment of N-linked, O-linked, and ceramide-linked glycosylation [PMID:21047787, PMID:21080064, PMID:7962052]. Compound heterozygous loss-of-function mutations in COG2 cause a congenital disorder of glycosylation (CDG) characterized by defective sialylation and galactosylation [PMID:24784932].\",\n  \"teleology\": [\n    {\n      \"year\": 1994,\n      \"claim\": \"Cloning of the LDLC (COG2) cDNA and complementation of ldlC CHO mutants revealed that COG2 encodes a peripheral Golgi protein required for multiple glycosylation pathways, and that its Golgi localization depends on LDLB (COG1), establishing the first subunit-dependency within the COG complex.\",\n      \"evidence\": \"cDNA complementation of ldlC CHO mutants, immunofluorescence, brefeldin A treatment\",\n      \"pmids\": [\"7962052\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\n        \"Direct physical interaction interface between COG2 and COG1 was not mapped\",\n        \"Mechanism by which COG2 supports glycosylation enzyme retention was not determined\",\n        \"Whether COG2 loss affects glycolipid pathways specifically was not tested\"\n      ]\n    },\n    {\n      \"year\": 2010,\n      \"claim\": \"Studies in Cog2-null CHO cells demonstrated that COG2 is required for proper Golgi retention of specific glycolipid-processing enzymes (SMS1 and SialT1), linking the COG complex to sphingomyelin synthesis and ganglioside biosynthesis and showing that COG2-dependent retrograde trafficking controls enzyme localization rather than enzyme expression.\",\n      \"evidence\": \"Lipid biochemistry, fluorescence microscopy of SMS1 and SialT1, co-immunoprecipitation, Cog2 rescue transfection in ldlC CHO cells\",\n      \"pmids\": [\"21047787\", \"21080064\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\n        \"Whether COG2 directly contacts SMS1 or SialT1, or acts indirectly through vesicle tethering, was not resolved\",\n        \"The SNARE machinery engaged by COG2 in retrograde trafficking was not identified\",\n        \"Quantitative contribution of each COG subunit to glycolipid enzyme retention is unknown\"\n      ]\n    },\n    {\n      \"year\": 2014,\n      \"claim\": \"Identification of compound heterozygous COG2 mutations in a CDG patient established COG2 as a human disease gene and showed that partial loss of COG2 destabilizes COG3 and COG4, revealing lobe A subunit interdependence in vivo.\",\n      \"evidence\": \"Trio-based whole-exome sequencing, RT-PCR, western blot of patient fibroblasts, serum glycoprotein analysis\",\n      \"pmids\": [\"24784932\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\n        \"Genotype–phenotype correlation across different COG2 mutations has not been established\",\n        \"Whether COG2-CDG phenotype arises primarily from destabilization of lobe A or from loss of COG2-specific functions is unclear\",\n        \"No rescue experiment in patient cells was performed\"\n      ]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"The structural basis of COG2's role within the COG complex, the identity of its direct cargo-sorting signals or SNARE partners, and whether COG2 has functions independent of the octameric COG complex remain unresolved.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Low\",\n      \"gaps\": [\n        \"No high-resolution structure of COG2 or COG2-containing subcomplexes has been reported\",\n        \"Direct binding partners among SNAREs or vesicle coat proteins have not been identified for COG2 specifically\",\n        \"Whether COG2 participates in autophagy or non-Golgi trafficking pathways is untested\"\n      ]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0060090\", \"supporting_discovery_ids\": [1, 3]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005794\", \"supporting_discovery_ids\": [1, 2, 3]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-392499\", \"supporting_discovery_ids\": [0, 1, 2, 3]},\n      {\"term_id\": \"R-HSA-5653656\", \"supporting_discovery_ids\": [1, 2, 3]},\n      {\"term_id\": \"R-HSA-1430728\", \"supporting_discovery_ids\": [2, 3]},\n      {\"term_id\": \"R-HSA-1643685\", \"supporting_discovery_ids\": [0]}\n    ],\n    \"complexes\": [\"COG complex\"],\n    \"partners\": [\"COG1\", \"COG3\", \"COG4\", \"SMS1\", \"SialT1\"],\n    \"other_free_text\": []\n  }\n}\n```\n\n--- ROUND 2 (R2/R3, augmented corpus) ---\n\n```json\n{\n  \"mechanistic_narrative\": \"COG2 is a core subunit of the eight-subunit conserved oligomeric Golgi (COG) complex that functions as a peripheral membrane tethering factor essential for intra-Golgi retrograde vesicular trafficking, thereby maintaining the steady-state localization of resident Golgi glycosyltransferases and normal Golgi morphology [PMID:11980916, PMID:27066481]. Within the complex, COG2 directly binds COG1, COG3, and COG4, and its own Golgi association depends on COG1 and is sensitive to brefeldin A; COG2 also interacts with the vesicle-tethering factor p115 to promote Golgi ribbon integrity during interphase [PMID:7962052, PMID:15047703, PMID:17274799]. Loss of COG2 causes widespread defects in N-linked, O-linked, and ceramide-linked glycosylation, including mislocalization of sphingomyelin synthase SMS1 and the glycolipid sialyltransferase SialT1, leading to reduced sphingomyelin synthesis and blocked GM3 production [PMID:21047787, PMID:21080064, PMID:27066481]. Biallelic COG2 mutations cause a congenital disorder of glycosylation (CDG) characterized by impaired sialylation and galactosylation and reduced COG2/COG3/COG4 protein levels [PMID:24784932].\",\n  \"teleology\": [\n    {\n      \"year\": 1994,\n      \"claim\": \"Identification of COG2 (LDLC/ldlCp) as a peripheral Golgi protein whose localization depends on COG1 (LDLB) established that loss of a single factor could produce pleiotropic defects in multiple medial- and trans-Golgi glycosylation pathways.\",\n      \"evidence\": \"cDNA cloning, immunofluorescence, BFA treatment, and somatic cell genetics in ldlB/ldlC CHO mutants\",\n      \"pmids\": [\"7962052\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\n        \"Identity and stoichiometry of the native complex containing ldlCp were unknown\",\n        \"Mechanism by which COG1 controls COG2 Golgi recruitment was unresolved\",\n        \"Whether ldlCp function is conserved beyond CHO cells was untested\"\n      ]\n    },\n    {\n      \"year\": 2002,\n      \"claim\": \"Biochemical purification and EM imaging revealed that COG2 is an integral subunit of an eight-subunit COG complex with a bilobed ~37-nm architecture, establishing the quaternary context in which COG2 operates.\",\n      \"evidence\": \"Co-purification, deep-etch EM, and genetic complementation of ldlB/ldlC CHO mutants\",\n      \"pmids\": [\"11980916\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\n        \"Which subunit–subunit contacts hold the complex together was unknown\",\n        \"Atomic-resolution structure of the complex was lacking\"\n      ]\n    },\n    {\n      \"year\": 2004,\n      \"claim\": \"Systematic binary interaction mapping showed that COG2 directly contacts COG1, COG3, and COG4, placing COG2 at a hub position within lobe A of the complex.\",\n      \"evidence\": \"In vitro translation and reciprocal co-immunoprecipitation of all eight COG subunit pairs\",\n      \"pmids\": [\"15047703\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\n        \"Structural basis for these interactions was not determined\",\n        \"Functional consequences of disrupting individual COG2 contacts were not tested\"\n      ]\n    },\n    {\n      \"year\": 2007,\n      \"claim\": \"Discovery that COG2 physically interacts with the vesicle-tethering factor p115 (via its HR2 domain) and that this interaction is required for Golgi ribbon reformation linked the COG complex to the broader tethering machinery and revealed cell-cycle-dependent regulation of this connection.\",\n      \"evidence\": \"Co-IP with p115 deletion mutants, Golgi morphology rescue in p115-knockdown cells, cell-cycle analysis\",\n      \"pmids\": [\"17274799\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\n        \"Whether additional COG subunits contribute to p115 interaction was not addressed\",\n        \"Mechanism of mitotic uncoupling of the p115–COG2 interaction was unexplored\"\n      ]\n    },\n    {\n      \"year\": 2010,\n      \"claim\": \"Studies in COG2-null cells demonstrated that COG2 is required not only for glycoprotein processing but also for sphingomyelin synthesis (via SMS1 Golgi retention) and glycolipid synthesis (via SialT1 Golgi localization), broadening the functional scope of the COG complex to lipid-linked glycosylation pathways.\",\n      \"evidence\": \"SM content measurement, SMS activity assays, GM3 quantification, SialT1 co-IP with COG1, and COG2 rescue transfection in ldlC CHO cells\",\n      \"pmids\": [\"21047787\", \"21080064\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\n        \"Whether COG2 directly contacts glycosyltransferases or acts indirectly through vesicular recycling was unresolved\",\n        \"Extent of lipid glycosylation defects in human patients was unknown\"\n      ]\n    },\n    {\n      \"year\": 2014,\n      \"claim\": \"Identification of biallelic COG2 mutations in a patient with congenital disorder of glycosylation demonstrated the clinical relevance of COG2 and showed that partial loss of function destabilizes lobe A partners COG3 and COG4.\",\n      \"evidence\": \"Trio whole-exome sequencing, RT-PCR for nonsense-mediated decay, transferrin isoelectrofocusing, Western blotting of patient fibroblasts\",\n      \"pmids\": [\"24784932\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\n        \"Only a single family was reported; genotype–phenotype spectrum remained narrow\",\n        \"Whether the missense allele retains partial complex assembly was not tested structurally\"\n      ]\n    },\n    {\n      \"year\": 2016,\n      \"claim\": \"CRISPR knockout of all eight COG subunits in a uniform genetic background showed that COG2 loss produces among the most severe glycosylation and trafficking defects, confirming its central role in the complex and its non-redundancy with other subunits.\",\n      \"evidence\": \"CRISPR/Cas9 KO in HEK293T cells, flow cytometry with lectins/toxins, mass spectrometric N-glycan profiling, immunofluorescence\",\n      \"pmids\": [\"27066481\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\n        \"High-resolution structure of COG2 within the assembled complex remains unresolved\",\n        \"Cargo specificity of COG-dependent retrograde vesicles is incompletely catalogued\"\n      ]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"The structural basis of COG2's hub role—how it simultaneously engages COG1, COG3, COG4, and p115—and the precise cargo repertoire of COG2-dependent retrograde vesicles remain open questions.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"High\",\n      \"gaps\": [\n        \"No high-resolution structure of COG2 or the lobe A sub-complex\",\n        \"Full inventory of Golgi enzymes dependent on COG2-mediated recycling is lacking\",\n        \"Therapeutic strategies for COG2-CDG have not been developed\"\n      ]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0060090\", \"supporting_discovery_ids\": [2, 4]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005794\", \"supporting_discovery_ids\": [0, 1, 5, 6, 8]},\n      {\"term_id\": \"GO:0031410\", \"supporting_discovery_ids\": [3, 8]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-5653656\", \"supporting_discovery_ids\": [3, 4, 8]},\n      {\"term_id\": \"R-HSA-392499\", \"supporting_discovery_ids\": [0, 5, 6, 7, 8]},\n      {\"term_id\": \"R-HSA-1430728\", \"supporting_discovery_ids\": [5, 6]},\n      {\"term_id\": \"R-HSA-1643685\", \"supporting_discovery_ids\": [7]}\n    ],\n    \"complexes\": [\"COG complex\"],\n    \"partners\": [\"COG1\", \"COG3\", \"COG4\", \"p115\", \"SMS1\", \"SialT1\"],\n    \"other_free_text\": []\n  }\n}\n```"}